CATALOGO DEI PRODOTTI DELLA RICERCA

VISCO, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.873
AS - Asia 4.300
EU - Europa 4.263
SA - Sud America 798
AF - Africa 71
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 14.329
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.772
SG - Singapore 1.637
CN - Cina 1.602
RU - Federazione Russa 1.371
GB - Regno Unito 685
BR - Brasile 663
HK - Hong Kong 505
FR - Francia 400
DE - Germania 376
IE - Irlanda 354
IT - Italia 315
SE - Svezia 263
VN - Vietnam 223
FI - Finlandia 179
UA - Ucraina 128
KR - Corea 95
NL - Olanda 54
AR - Argentina 51
CA - Canada 46
IN - India 42
AT - Austria 38
BD - Bangladesh 35
ID - Indonesia 33
EC - Ecuador 32
MX - Messico 32
JP - Giappone 28
ZA - Sudafrica 23
TR - Turchia 22
CO - Colombia 18
BE - Belgio 17
PL - Polonia 17
IQ - Iraq 16
TG - Togo 15
AU - Australia 13
CL - Cile 13
ES - Italia 11
MA - Marocco 11
LT - Lituania 10
UZ - Uzbekistan 10
PE - Perù 9
PY - Paraguay 8
SA - Arabia Saudita 8
EU - Europa 7
GR - Grecia 7
PK - Pakistan 7
TT - Trinidad e Tobago 6
CH - Svizzera 5
KE - Kenya 5
PT - Portogallo 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
AZ - Azerbaigian 4
DK - Danimarca 4
EG - Egitto 4
IL - Israele 4
TN - Tunisia 4
BG - Bulgaria 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
MY - Malesia 3
NP - Nepal 3
TW - Taiwan 3
VE - Venezuela 3
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MD - Moldavia 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BH - Bahrain 1
BW - Botswana 1
CD - Congo 1
CI - Costa d'Avorio 1
CM - Camerun 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
IR - Iran 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MU - Mauritius 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
Totale 14.323
Salva come PNG Salva come JPEG
Città #
Dallas 903
Singapore 679
Southend 592
Chandler 569
Jacksonville 561
Hong Kong 502
Dublin 349
Beijing 302
Ashburn 288
Moscow 279
Munich 161
Lawrence 152
Princeton 152
Wilmington 150
Jinan 130
Woodbridge 113
New York 112
Nanjing 111
Shenyang 110
The Dalles 103
Helsinki 100
Los Angeles 90
Redondo Beach 83
Houston 76
Tianjin 69
Hebei 68
Buffalo 63
São Paulo 63
Ho Chi Minh City 62
Verona 48
Zhengzhou 47
Sindelfingen 44
Hanoi 43
London 42
Taizhou 40
Changsha 38
Jiaxing 37
Haikou 36
Ann Arbor 35
Columbus 35
Dearborn 35
Redmond 35
Grafing 33
Guangzhou 33
Dong Ket 31
Hangzhou 31
Milan 31
Ningbo 31
Santa Clara 30
Nanchang 28
Taiyuan 27
Seattle 26
Turku 26
Lanzhou 24
Norwalk 24
San Francisco 24
Tokyo 24
Brooklyn 23
Jakarta 23
Council Bluffs 22
Boston 20
Nuremberg 20
Redwood City 20
Belo Horizonte 19
Frankfurt am Main 19
Vienna 19
Fuzhou 18
Rio de Janeiro 18
Toronto 17
Chicago 16
Guayaquil 16
Seoul 16
Washington 16
Lomé 15
Amsterdam 14
Johannesburg 14
Boardman 13
Lappeenranta 13
Salvador 13
Brussels 12
Curitiba 12
Falkenstein 12
Mexico City 12
Roubaix 12
Warsaw 12
Atlanta 11
Denver 11
Montreal 11
Stockholm 11
Bologna 10
Brasília 10
Chennai 10
Tashkent 10
Phoenix 9
Xi'an 9
Zibo 8
Baghdad 7
Campinas 7
Dhaka 7
Fairfield 7
Totale 8.524
Salva come PNG Salva come JPEG
Nome #
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 181
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia 163
Integrated single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia 150
Computer-based drug management in a bone marrow transplant unit: a suitable tool for multiple prescriptions even in critical conditions 142
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 140
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia 138
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 137
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? 134
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma 132
Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia 132
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 128
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 128
Serum levels of soluble CD30 improve international prognostic score in predicting the outcome of advanced Hodgkin's lymphoma 123
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 120
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma 118
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma 118
A prognostic model for patients with lymphoma and {COVID}-19: a multicentre cohort study 118
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 117
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 116
Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival 116
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? 116
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 115
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 115
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice 113
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 112
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 111
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma 110
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy 110
Life-Threatening Protein-Losing Enteropathy Due To Human Cytomegalovirus Infection Upon Immunochemotherapy 110
Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease 108
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma 108
B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities 108
A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks 107
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 106
Toxoplasma Gondii encephalitis in two allogeneic bone marrow transplant recipients: an emerging infection after heavy immunosoppressive therapy 105
Autoimmune cytopenias in chronic lymphocytic leukemia 105
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 104
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 104
Genetic and phenotypic attributes of splenic marginal zone lymphoma 98
High dose sequential chemotherapy (HDSC) as salvage therapy for patients with malignant lymphomas: prognostic factors and clinical outcomes 97
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation 97
A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report 96
EPSTEIN-BARR VIRUS DNA LOAD IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF CLINICAL COURSE AND SURVIVAL 96
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 95
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. 95
Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome 95
Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis 95
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma 94
Bendamustine plus rituximab: is it a BRIGHT idea? 94
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 94
Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi 92
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 91
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 91
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. 90
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia 90
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 90
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and {CAR}-T Cell Therapy 90
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors 89
Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases 89
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 89
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 88
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia 87
Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. 86
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 84
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis 83
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 83
Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment 82
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 82
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 82
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease 80
Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status 80
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine 80
Computerized drug management in a Bone Marrow Transplant Unit: towards an improvement of hospital drug management 79
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 79
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study 79
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma 78
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 78
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study 78
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 77
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries 77
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program 77
Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia 76
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 76
Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia 76
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 75
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 75
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma 75
Long‐term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients 74
Computer-based drug management in a bone marrow transplant unit:a suitable tool for multiple prescriptions even in critical conditions 74
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? 74
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 74
P53 and p21waf1 expression by immunohistochemistry in diffuse large B-cell lymphoma has a strong and independent impact on survival of patients with germinal center phenotype 73
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study 73
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma 73
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 73
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines 72
STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target 72
Aggressive B-cell Lymphoma with {MYC}/{TP}53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents 72
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma 71
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program 70
Totale 9.762
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.406
article - articoli 59.175
book - libri 0
conference - conferenze 2.231
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122.812
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021568 0 0 0 0 142 166 6 18 24 20 139 53
2021/2022915 52 197 17 44 35 27 46 64 35 29 58 311
2022/20231.992 168 170 210 271 186 523 31 114 214 18 49 38
2023/20241.080 38 93 82 103 99 215 50 106 12 33 174 75
2024/20253.537 204 188 87 571 132 141 176 213 506 271 313 735
2025/20264.300 738 885 811 1.713 153 0 0 0 0 0 0 0
Totale 14.588